Group 1 - The company, Taiji Group (600129), announced a plan to repurchase its shares through centralized bidding, with a total repurchase amount not less than 80 million yuan and not exceeding 120 million yuan [1] - The maximum repurchase price is set at 28.03 yuan per share, and the total number of shares expected to be repurchased ranges from 2.8541 million to 4.2811 million shares, which represents 0.51% to 0.77% of the company's total share capital [1] - All repurchased shares will be used for cancellation, thereby reducing the company's registered capital [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-052 重庆太极实业（集团）股份有限公司 2025 年半年度业绩预减公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 重要内容提示： 1 1.本期业绩预告适用于实现盈利，且净利润与上年同期相比下降 50% 以上的情形。 2．重庆太极实业（集团）股份有限公司（以下简称：公司）预计 2025 年半年度归属于上市公司股东的净利润约为 13,900 万元，与上年 同期相比，下降约 35,561.25 万元，同比降幅约 71.90%。 3．公司预计 2025 年半年度归属于上市公司股东的扣除非经常性损 益的净利润约为 12,000 万元，与上年同期相比，下降约 34,994.60 万元， 同比降幅约 74.47%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 经财务部门初步测算，预计 2025 年半年度归属于上市公司股东的净 利润约为 13,900 万元，与上年同期相比，下降约 35, ...

Core Points - The company held its 29th meeting of the 10th Board of Directors on July 7, 2025, where several key resolutions were passed, including the appointment of a new accounting firm and changes in board composition [1][2][3][4][5][6][7][8][9][10][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71] Group 1 - The company plans to change its accounting firm from Tianjian CPA to Lixin CPA for the 2025 financial report and internal control audit due to the expiration of the service term of the former firm [1][45][46] - The board approved the addition of a new director, Ms. Yu Xingyue, nominated by the controlling shareholder, with her term starting from the approval date by the shareholders' meeting [3][4][57][58] - The company intends to simplify its structure by canceling the indirect holding subsidiary, Hainan Taiji Pharmaceutical Import and Export Co., Ltd., to focus on its core business [5][62][63][64] Group 2 - The company will acquire 100% of the shares of Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd. by purchasing the 90% and 10% stakes held by its subsidiaries for a nominal price of 1 yuan [6][31][32] - The company’s subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, will acquire 40% of Hainan Taiji Marine Pharmaceutical Co., Ltd. for 248,000 yuan, increasing its ownership from 60% to 100% [7][31][32] - The company has decided to cancel the supervisory board, transferring its responsibilities to the audit committee of the board, and will revise its articles of association accordingly [8][69][70]

Group 1 - The company held its 29th meeting of the 10th Board of Directors on July 7, 2025, with 11 out of 12 directors present, and the meeting was deemed legal and effective [1][2] - The company proposed to change its accounting firm from Tianjian Accounting Firm to Lixin Accounting Firm due to the expiration of the service term, which requires shareholder approval [1][2] - The company plans to supplement its board of directors by nominating Ms. Yu Xingyue, with her term starting from the approval date by the shareholders [2][6] Group 2 - The company intends to simplify its structure by liquidating its indirect subsidiary, Hainan Taiji Pharmaceutical Import and Export Co., Ltd., to focus on its core business [2][3] - The company will acquire 100% equity of Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd. by purchasing shares from its subsidiaries for a nominal price of 1 yuan [3][4] - The company’s subsidiary, Chongqing Fuling Pharmaceutical Factory, will acquire 40% equity of Hainan Taiji Marine Pharmaceutical Co., Ltd. for 2.48 million yuan, increasing its ownership from 60% to 100% [4][5] Group 3 - The company approved the cancellation of the supervisory board and the revision of its articles of association, pending shareholder approval [5][6] - The company revised several governance documents, including the rules for shareholder meetings and board meetings, which will also be submitted for shareholder approval [5][6] - The company announced the convening of its second extraordinary general meeting of shareholders in 2025 [5][6]

Group 1 - The company, Chongqing Taiji Industrial (Group) Co., Ltd., is holding its second extraordinary general meeting of shareholders in 2025 on August 6, 2025, at 14:00 [1][4] - The meeting will take place at the company's conference room located at 1201, 18 Hengshan East Road, Yubei District, Chongqing [1][4] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [1][4][5] Group 2 - The meeting will include non-cumulative voting proposals, and all A-share shareholders are eligible to vote [2][3] - The board of directors has approved the agenda for the meeting during its 29th meeting on July 9, 2025, and the details have been disclosed in various financial newspapers and the Shanghai Stock Exchange website [4][5] - There are no related shareholders that need to abstain from voting on the special resolution proposals [4] Group 3 - Shareholders must be registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, by the close of trading on July 29, 2025, to attend the meeting [5] - The company allows proxy representation for shareholders, and specific identification and authorization documents are required for attendance [5][6] - The company has provided an email contact for inquiries related to the meeting [6]

Core Points - The company, Chongqing Taiji Industry (Group) Co., Ltd., was established on December 28, 1993, and is a publicly listed company since November 18, 1997, on the Shanghai Stock Exchange [3][4][9] - The registered capital of the company is RMB 556.890744 million [3][9] - The company's business philosophy focuses on health and wellness, aiming to become a leading enterprise in traditional Chinese medicine with a strong emphasis on innovation and technology [6][14] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [4][5] - The company has established a Communist Party organization to conduct party activities within the company [6][14] - The company’s senior management includes the general manager, deputy general managers, board secretary, and financial director [5][6] Business Scope - The company’s business scope includes the production and retail of pharmaceuticals, health food production, and various medical device manufacturing [6][7] - The company is also involved in research and development in medicine and technology, as well as agricultural products [7][8] Share Structure - The company has issued a total of 556.890744 million shares, all of which are ordinary shares [9][10] - The company can increase its capital through various legal means, including public offerings and employee stock ownership plans [10][11] - The company is restricted from repurchasing its shares except under specific circumstances, such as capital reduction or mergers [10][11] Shareholder Rights - Shareholders have rights to dividends, voting, and the ability to request meetings and propose agenda items [16][17] - Shareholders holding more than 3% of shares for over 180 days can request to review the company's financial records [17][18] - The company must provide legal opinions on the validity of shareholder meetings and decisions [26][27] Governance - The company’s board of directors is responsible for major decisions, including profit distribution and capital changes [24][25] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [26][27] - The company has established procedures for calling and conducting shareholder meetings, ensuring transparency and compliance with legal requirements [28][29]

Core Viewpoint - The document outlines the independent director working system of Chongqing Taiji Industry (Group) Co., Ltd., emphasizing the importance of independent directors in corporate governance and their role in protecting the interests of minority shareholders [1][2]. Summary by Sections General Principles - The system aims to standardize operations, enhance the role of independent directors, and improve corporate governance for high-quality development [1]. - Independent directors must not hold other positions within the company and should have no direct or indirect interests that could affect their independent judgment [2]. Qualifications and Appointment of Independent Directors - Independent directors must maintain independence and cannot be individuals with certain relationships or interests in the company [5]. - The board must have at least one accounting professional among the independent directors, and independent directors should not serve on more than three domestic companies [6][5]. Responsibilities and Duties of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [9]. - They have special rights, including hiring external consultants and proposing meetings [15]. Communication and Reporting - Independent directors must attend board meetings and can communicate with the board secretary to discuss agenda items [10]. - They are required to submit annual reports detailing their activities and interactions with minority shareholders [29]. Support and Compensation - The company must provide necessary working conditions and support for independent directors to fulfill their duties [31]. - Independent directors are entitled to compensation that reflects their responsibilities, and the company must cover expenses related to hiring professional services [36][19].

重庆太极实业（集团）股份有限公司 董事会审计委员会实施细则 （2025 年 7 月修订） 第一章 总 则 第一条 为了推进重庆太极实业（集团）股份有限公司 （以下简称公司）提高公司治理水平,规范公司董事会审计 委员会的运作，根据《中华人民共和国公司法》（以下简称 《公司法》）、 《中华人民共和国证券法》 《上市公司治理准则 （2025 年修正）》《上市公司独立董事管理办法（2025 年修 正）》《上海证券交易所股票上市规则（2025 年 4 月修订）》 （以下简称《股票上市规则》）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等 相关法律、行政法规、部门规章、交易所业务规则以及《重 庆太极实业（集团）股份有限公司章程》（以下简称《公司 章程》）的要求，公司特设立董事会审计委员会，并制定本 实施细则。 第二条 审计委员会是董事会下设的专门委员会，对董 事会负责，向董事会报告工作，行使《公司法》规定的监事 会的职权，负责公司内、外部审计工作的监督、审核、沟通 及协调。 第三条 审计委员会成员须保证足够的时间和精力履 行委员会的工作职责，勤勉尽责，切实有效地监督公司的外 ...

重庆太极实业（集团）股份有限公司 董事会审计委员会实施细则 （2025 年 7 月修订） 第一章 总 则 第一条 为了推进重庆太极实业（集团）股份有限公司 （以下简称公司）提高公司治理水平,规范公司董事会审计 委员会的运作，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》《上市公司治理准则 （2025 年修正）》《上市公司独立董事管理办法（2025 年修 正）》《上海证券交易所股票上市规则（2025 年 4 月修订）》 （以下简称《股票上市规则》）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等 相关法律、行政法规、部门规章、交易所业务规则以及《重 庆太极实业（集团）股份有限公司章程》（以下简称《公司 章程》）的要求，公司特设立董事会审计委员会，并制定本 实施细则。 第二条 审计委员会是董事会下设的专门委员会，对董 事会负责，向董事会报告工作，行使《公司法》规定的监事 会的职权，负责公司内、外部审计工作的监督、审核、沟通 及协调。 第三条 审计委员会成员须保证足够的时间和精力履 行委员会的工作职责，勤勉尽责，切实有效地监督公司的外 部 ...

重庆太极实业（集团）股份有限公司 章 程 二 0 二五年七月 - 1 - | 第一章 | 总则 | | --- | --- | | 第二章 | 经营宗旨和范围 - 5 - | | 第三章 | 股份 . | | 第四章 | 公司党委 - 10 - | | 第五章 | 股东和股东会 - 10 - | | 第六章 | 董事和董事会 . | | 第七章 | 高级管理人员 - 53 - | | 第八章 | 财务会计制度、利润分配和审计 - 56 - | | 第九章 | 通知和公告 | | 第十章 | 合并、分立、增资、减资、解散和清算 - 65 - | | | 第十一章 修改章程 | | | 第十二章 附则 | 第一章 总 则 第一条 为维护重庆太极实业（集团）股份有限公司（以 下简称公司）、股东、职工和债权人的合法权益，规范公司的组 织和行为，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）和其他有关 规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股 份有限公司。 公司于 1993 年 12 月 28 日在涪陵市工商行政管理局注册登 记，取得营 ...